Senseonics (NYSE:SENS) announced that it anticipates the FDA to decide within weeks on approval of its new CGM system.
The company seeks a premarket approval supplement for the next-generation Eversense 180-day implantable continuous glucose monitoring (CGM) system. Data presented earlier this year demonstrated strong accuracy. The next-generation Eversense matched performance levels compared to the current 90-day sensor available in the U.S. — but with reduced calibration, down to one per day, with the duration extended to 180 days.
Get the full story at our sister site, Drug Delivery Business News.
